Sanofi’s Lunsekimig Trial Reaches Key Milestone in Atopic Dermatitis Pipeline

Sanofi (SNYNF) announced an update on their ongoing clinical study.

The Phase 2b study titled “A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of 3 Subcutaneous Dose Regimens of Lunsekimig (SAR443765) in Adult Participants With Moderate-to-severe Atopic Dermatitis” tests Sanofi’s new drug in adults who do not respond well to creams. The goal is to see if Lunsekimig can control symptoms and stay safe enough to support larger late-stage trials that could expand Sanofi’s dermatology portfolio.

The treatment under review is Lunsekimig, also known as SAR443765, given by subcutaneous injection as a solution in a vial. It is used as a stand-alone drug and compared to a matching placebo injection, aiming to calm the immune response that drives moderate-to-severe atopic dermatitis and reduce flare-ups and skin damage.

The study uses a randomized design, meaning patients are assigned by chance to Lunsekimig or placebo across six arms that test three different dosing regimens. It is triple-blind, so patients, doctors, and study staff do not know who gets the drug or placebo, and the main goal is to evaluate treatment benefit rather than prevention or diagnosis.

The trial runs for about 36 weeks per patient including screening, 24 weeks of treatment, and 8 weeks of safety follow-up, which helps capture both short- and mid-term effects. Key registry dates show the study was first submitted on 2025-01-17 and last updated on 2026-04-20, while the overall status is listed as completed with no posted results yet, signaling that data analysis is likely in progress.

For investors, this update marks another step in Sanofi’s effort to deepen its immunology franchise beyond existing assets like Dupixent and sustain long-term growth in inflammatory skin disease. Positive Phase 2b data could support a higher valuation for SNYNF by reinforcing future revenue potential and competitive positioning against players such as Amgen, Eli Lilly, and AbbVie in biologics and targeted therapies.

Short term, the absence of public results may keep the stock reaction muted, but any later readout suggesting strong efficacy with a clean safety profile could lift sentiment and raise expectations for a Phase 3 program and eventual market entry. The study is now completed and recently updated, with further details available on the ClinicalTrials portal as Sanofi advances analysis and prepares for the next development steps.

To learn more about SNYNF’s potential, visit the Sanofi drug pipeline page.